BNP Paribas Financial Markets Acquires 84,543 Shares of Disc Medicine, Inc. $IRON

BNP Paribas Financial Markets lifted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 224.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 122,153 shares of the company’s stock after buying an additional 84,543 shares during the quarter. BNP Paribas Financial Markets’ holdings in Disc Medicine were worth $9,700,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Disc Medicine by 22.1% during the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock valued at $140,371,000 after purchasing an additional 319,621 shares during the last quarter. Geode Capital Management LLC grew its holdings in Disc Medicine by 9.0% in the 4th quarter. Geode Capital Management LLC now owns 684,958 shares of the company’s stock worth $54,402,000 after acquiring an additional 56,807 shares during the last quarter. Jennison Associates LLC bought a new stake in Disc Medicine in the 4th quarter worth $42,252,000. Vestal Point Capital LP grew its holdings in Disc Medicine by 257.1% in the 3rd quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock worth $33,040,000 after acquiring an additional 360,000 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its holdings in Disc Medicine by 50.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 450,000 shares of the company’s stock worth $23,832,000 after acquiring an additional 150,000 shares during the last quarter. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Trading Down 1.8%

NASDAQ:IRON opened at $65.80 on Tuesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. The firm has a market capitalization of $2.51 billion, a P/E ratio of -9.94 and a beta of 0.93. Disc Medicine, Inc. has a one year low of $40.00 and a one year high of $99.50. The company’s 50-day simple moving average is $67.72 and its 200 day simple moving average is $73.10.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.03). As a group, analysts forecast that Disc Medicine, Inc. will post -6.74 EPS for the current fiscal year.

Insider Activity

In other Disc Medicine news, insider William Jacob Savage sold 5,731 shares of Disc Medicine stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $66.38, for a total value of $380,423.78. Following the completion of the transaction, the insider directly owned 79,480 shares of the company’s stock, valued at approximately $5,275,882.40. The trade was a 6.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jean M. Franchi sold 6,257 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the transaction, the chief financial officer directly owned 64,333 shares of the company’s stock, valued at $4,454,416.92. The trade was a 8.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 12,388 shares of company stock valued at $841,258 over the last ninety days. Corporate insiders own 3.76% of the company’s stock.

Analysts Set New Price Targets

IRON has been the topic of a number of recent analyst reports. Wells Fargo & Company raised their price target on shares of Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Cantor Fitzgerald cut their target price on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th. Wedbush cut their target price on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th. Finally, Stifel Nicolaus cut their target price on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Disc Medicine currently has an average rating of “Moderate Buy” and a consensus target price of $105.30.

Disc Medicine Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.